Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 9Carcinoma, Non-Small-Cell Lung 9Melanoma 7Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Neoplasms 4Carcinoma, Transitional Cell 4Neoplasm Metastasis 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable or Metastatic Solid Tumors 1Solid Tumors 1Skin Neoplasms 1Recurrence 1Microsatellite Instability 1Mesothelioma 1Hematologic Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1

Interventions

pembrolizumab 15Nivolumab 10Ipilimumab 7cemiplimab 6dabrafenib 4binimetinib 4Dacarbazine 4trametinib 3encorafenib 3Drug Therapy 3Allovectin-7 3zanolimumab 2talabostat 2lifileucel 2aldesleukin 2Vemurafenib 2Tablets 2Semaxinib 2Intravital Microscopy 2Interleukin-2 2Fluorouracil 2vitespin 1veliparib 1varlilumab 1tozuleristide 1tin etiopurpurin 1tilsotolimod 1spartalizumab 1sotigalimab 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Skin Neoplasms × epacadostat × Clear all
NCT01604889 2026-04-21

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Incyte Corporation

Phase 1/2 Terminated
50 enrolled
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡